Biogen Inc.

NASDAQ Global Select
Back to all articles
Bullish +75

Biogen Idec Inc. (BIIB): This Biotechnology Stock Is On The Roll

🩸 Biogen Idec presented new clinical data at the ISTH Congress supporting ELOCTATE for hemophilia A and ALPROLIX for hemophilia B.

💉 ALPROLIX demonstrated the ability to control more than 90% of bleeds with a single injection in recent trials.

📊 ALPROLIX exhibits more than double the longevity of Pfizer's BeneFIX, a key competitor in the Hemophilia B market.

💰 Biogen Idec reported 2012 annual revenues of $5.52 billion, representing an increase of over 8% from the previous year.

🧬 The company utilizes proprietary monomeric Fc fusion technology to delay factor destruction and cycle it back into the bloodstream.

📈 Analysts expect Q2 2013 EPS of $1.91, up from $1.82 in the same quarter prior year.

💊 TECFIDERA, a multiple sclerosis drug launched this year, is expected to generate around $422 million in sales for 2013.

🤝 ELOCTATE and ALPROLIX were acquired from Syntonix Pharmaceuticals in January 2007 as part of Biogen's hemophilia portfolio.

📅 The company is scheduled to report its second quarter 2013 financial figures on July 25, 2013.

🎯 Full year analyst expectations for EPS are set at $7.90 compared to the reported $6.54 for FY 2012.

Bullish Signals
  • New clinical data shows ALPROLIX controls over 90% of bleeds with a single injection, indicating strong efficacy.
  • ALPROLIX has more than double the longevity of Pfizer's BeneFIX, offering a competitive advantage in Hemophilia B treatment.
  • Biogen Idec achieved an 8% revenue increase to $5.52 billion in 2012, demonstrating solid financial growth.
  • Analysts project Q2 2013 EPS of $1.91, which is higher than the $1.82 reported in the same quarter last year.
  • The company's proprietary Fc fusion technology successfully extends the duration of clotting factors in the bloodstream.
  • TECFIDERA sales are expected to reach $422 million in 2013, contributing significantly to revenue growth.
Full Analysis
Biogen Idec Inc. (NASDAQ: BIIB) recently presented new clinical data at the ISTH Congress in Amsterdam supporting its hemophilia A candidate, ELOCTATE, and its hemophilia B candidate, ALPROLIX. Both products are being developed with Swedish Orphan Biovitrum AB using Biogen's proprietary Fc fusion technology designed to extend the longevity of clotting factors in the bloodstream. The new data indicates that a single injection of ALPROLIX helped control more than 90% of bleeds for hemophilia B patients, demonstrating superior efficacy compared to Pfizer's BeneFIX, which has double the longevity. ELOCTATE similarly shows potential for reducing injection frequency and effectively managing acute bleeding episodes in hemophilia A patients. Biogen Idec reported annual revenues of $5.52 billion in 2012, an increase of over 8% from the prior year. The company has a portfolio of ten approved drugs including TECFIDERA for multiple sclerosis, with analysts expecting 2013 sales to reach approximately $422 million. Financial figures for the second quarter of 2013 are scheduled to be reported on July 25, 2013. Analysts expect Biogen Idec to report Q2 2013 earnings per share (EPS) of $1.91 compared to $1.82 in the same quarter last year. For the full fiscal year, street expectations are set at $7.90 per share against the reported $6.54 for FY 2012. The company's acquisition of Syntonix Pharmaceuticals in January 2007 brought these hemophilia candidates into its portfolio.